Form 8-K - Current report:
SEC Accession No. 0000950170-23-029901
Filing Date
2023-06-26
Accepted
2023-06-26 17:01:31
Documents
13
Period of Report
2023-06-22
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20230622.htm   iXBRL 8-K 62980
2 EX-16.1 axsm-ex16_1.htm EX-16.1 3973
  Complete submission text file 0000950170-23-029901.txt   182054

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20230622.xsd EX-101.SCH 2451
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20230622_pre.xml EX-101.PRE 9441
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20230622_lab.xml EX-101.LAB 12806
7 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20230622_htm.xml XML 4543
Mailing Address ONE WORLD TRADE CENTER, 22ND FLOOR NEW YORK NY 10007
Business Address ONE WORLD TRADE CENTER, 22ND FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 231043044
SIC: 2834 Pharmaceutical Preparations